Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Lioresal®:Novartis Pharma Schweiz AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
M03BX01 - BaclofenATC-DDD Version 2016. Source: WHO
M - Musculo-Skeletal System
M03 - Muscle Relaxants

This group comprises peripherally, centrally and directly acting muscle relaxants.
See also G04BD - Drugs for urinary frequency and incontinence.

M03B - Muscle Relaxants, Centrally Acting Agents

This group comprises centrally acting muscle relaxants. Combined preparations are classified at separate 5th levels using the corresponding 50-series (comb. excl. psycholeptics), or the 70-series (comb. with psycholeptics):
The group is subdivided according to chemical structure.
Combinations with NSAIDs (M01A), analgesics (N02B) or corticosteroids (H02A) are classified here.

These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.
DDDs for combination products, see list on the website

M03BX - Other Centrally Acting Agents

Baclofen indicated for reduction of alcohol consumption is classified here.

M03BX01 - Baclofen
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home